GLP1R and heart failure: Tirzepatide demonstrated the greatest symptomatic improvement (KCCQ-CSS gain of 6.8 points over placebo), while the GLP-1 RA + SGLT2i combination yielded strong prognostic benefits, including a 36% relative risk reduction in heart failure events.